These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Ahmed MH; Khalil AA Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168 [TBL] [Abstract][Full Text] [Related]
29. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Lee S; Cannon CP Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475 [TBL] [Abstract][Full Text] [Related]
30. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
31. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
32. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function. Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498 [TBL] [Abstract][Full Text] [Related]
33. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors. Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601 [TBL] [Abstract][Full Text] [Related]